What Is It?
PT-141 (bremelanotide) is a synthetic peptide that acts on melanocortin receptors involved in central nervous system pathways related to sexual response. The FDA-approved product Vyleesi is specifically indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in certain premenopausal women. It is not FDA-approved for male sexual dysfunction, erectile dysfunction, or use in postmenopausal women. Any other use represents an off-label decision that requires provider review, including cardiovascular and blood-pressure evaluation.
What May It Support?
- Sexual response in the FDA-approved patient population
- Sexual wellness (being evaluated in off-label settings under provider review)
Which Programs May Include It?
Where It Fits
Activates melanocortin receptors (particularly MC4R) in the central nervous system, pathways associated with sexual response.
Do I Need Bloodwork?
Blood-pressure monitoring is important because PT-141 can transiently raise blood pressure and reduce heart rate. Follow-up is determined by the treating provider.
Likely baseline panel may include: Provider-determined; cardiovascular and blood-pressure evaluation typically required
Important Safety Information
Common side effects may include:
- Nausea (common, especially initially)
- Flushing
- Headache
- Injection-site reactions
- Vomiting
- Cough
- Fatigue
- Transient darkening of skin, gums, or moles (focal hyperpigmentation)
Focal hyperpigmentation of skin, face, or gums has been reported and may not fully resolve after discontinuation
Should not be used more than eight doses per month per the FDA-approved product label
Drug interactions: May reduce absorption of oral naltrexone and other medications; may interact with medications affecting blood pressure or heart rate. Provider should review the complete medication list.
Contraindications:
- Uncontrolled hypertension
- Known cardiovascular disease (case-by-case with provider clearance)
- Pregnancy
- Known hypersensitivity to bremelanotide
Regulatory Status
The FDA-approved bremelanotide product (Vyleesi) is indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women. It is not FDA-approved for male sexual dysfunction, erectile dysfunction, or use in postmenopausal women.
Frequently Asked Questions
Is PT-141 FDA-approved for men?
Is PT-141 the same as sildenafil or tadalafil?
Do I need bloodwork before starting?
How often can I use it?
Consultation
Treatment is not automatically provided. A licensed medical provider must review your history, symptoms, medications, laboratory results, and treatment goals before determining eligibility.